NCT00366782View on ClinicalTrials.gov

Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

February 28, 2011

Study Completion Date

June 30, 2011

Conditions
Paramyxoviridae InfectionsVirus Diseases
Interventions
BIOLOGICAL

rB/HPIV3

Live attenuated rB/HPIV3 vaccine given at a dose of 10\^6 TCID50

BIOLOGICAL

rB/HPIV3

Live attenuated rB/HPIV3 vaccine given at a dose of 10\^5 TCID50

BIOLOGICAL

Placebo

Placebo for rB/HPIV3 vaccine

Trial Locations (1)

21205

Center for Immunization Research, Baltimore

All Listed Sponsors
collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00366782 - Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults | Biotech Hunter | Biotech Hunter